pak 104p has been researched along with epirubicin in 1 studies
| Studies (pak 104p) | Trials (pak 104p) | Recent Studies (post-2010) (pak 104p) | Studies (epirubicin) | Trials (epirubicin) | Recent Studies (post-2010) (epirubicin) |
|---|---|---|---|---|---|
| 16 | 0 | 0 | 5,453 | 1,838 | 1,570 |
| Protein | Taxonomy | pak 104p (IC50) | epirubicin (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.75 | ||
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garnier-Suillerot, A; Marbeuf-Gueye, C; Quidu, P; Salerno, M | 1 |
1 other study(ies) available for pak 104p and epirubicin
| Article | Year |
|---|---|
Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclic P-Oxides; Daunorubicin; Depression, Chemical; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Fluoresceins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Nicotinic Acids; Tumor Cells, Cultured | 2000 |